Abstract:Background: High incidence of gastric cancer (GC), its aggressive clinical course, rapid tumor dissemination, low sensitivity to chemotherapy and lack of reliable laboratory diagnostic criteria urgently require a search for the most informative markers associated with key biologic properties of the tumors. Aim: Comparative analysis of galectin-3, matrix metalloproteinase (MMP)-2, and MMP-9 levels in peripheral blood of GC patients and healthy donors, assessment of association of these markers with clinical morphological characteristics of the disease, and prognosis of overall and relapse-free survival. Materials and methods: Sixty (60) primary treatment-nave GC patients (38 men, 22 women) aged 29 to 81 years and 90 healthy donors compatible with their age and sex were included into the study. Galectin-3 was measured in EDTA plasma, MMP-2 and MMP-9 in serum with standard direct enzyme immunoassay kits "Human MMP-2 (total)", "Human MMP-9 (total)", "Human Galectin-3" (RD Systems, USA). Results: Plasma galectin-3 concentration in the GC patients was significantly higher than in the healthy controls (median 12.9 and 10.6 ng/ml, respectively; p 0.0001). No difference in serum MMP-9 levels between GC patients and control subjects were found, while MMP-2 level in the control group was significantly higher, than in the GC patients (p = 0.039). No association between galectin-3, MMP-2, and MMP-9 blood levels in the GC patients could be identified. In contrast to GC patients, there was a positive correlation of plasma galectin-3 with age in the control group (rs = 0.51, p 0.005). No associations between the biomarkers levels in blood and clinical and morphological characteristics of GC were established, except MMP-9 being higher at Т4а invasion depth as compared to the earlier Т2 level. Marked differences in the overall survival depending on plasma galectin-3 levels were found, with the cut-off level of 12.9 ng/ml: the 5-year overall survival in the patients with low galectin-3 was better, than in those with its higher level (50 and 43%, respectively; however, the difference was non-significant, р 0.1). Both overall and relapse-free survival of the GC patients was higher in those with low ( 212 ng/ml) serum MMP-2: the 5-year overall survival in this group comprised 60% versus 23% in the patients with higher MMP-2 (p = 0.018). The difference in relapse-free survival was non-significant. Serum MMP-9 levels had no significant impact on the survival of GC patients. Conclusion: The ambiguous data on the clinical role of galectin-3, MMP-2, MMP-9 in GC obtained in this study indicate the necessity of further investigation of their possible utility for the diagnostics and prognosis of treatment results.

Both Serum and Tissue Galectin-1 Levels Are Associated with Adverse Clinical Features in Neuroblastoma.

Tumor and Serum Gamma-Glutamyl Transpeptidase, New Prognostic and Molecular Interpretation of an Old Biomarker in Gastric Cancer

NGAL Expression is Elevated in Both Colorectal Adenoma-Carcinoma Sequence and Cancer Progression and Enhances Tumorigenesis in Xenograft Mouse Models.

Exploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer

Prognostic and Diagnostic Significance of Galectins in Pancreatic Cancer: a Systematic Review and Meta-Analysis

Alteration of Serum IgG Galactosylation As a Potential Biomarker for Diagnosis of Neuroblastoma.

KIT Mutations Correlate with Higher Galectin Levels and Brain Metastasis in Breast and Non-Small Cell Lung Cancer

The relationship between circulating tumor cells in peripheral blood and clinical characteristics of pediatric neuroblastoma and prognostic evaluation

Correlation Analysis of Genetic Mutations and Galectin Levels in Breast Cancer Patients

NCAPG is a Potential Biomarker for Prognosis of Treatment in Children with High-risk Neuroblastoma

Prognostic Significance of Galectin-1 Expression in Patients with Cancer: a Meta-Analysis

Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy

Clinical and prognostic effects of Galectin-3 in elderly patients with colorectal cancer

Bioinformatic Identification of Neuroblastoma Microenvironment-Associated Biomarkers with Prognostic Value

Prognostic Values of Primary Tumor Textural Heterogeneity and Blood Biomarkers in High-risk Neuroblastoma

Circulating CEA-dNLR score predicts clinical outcome of metastatic gallbladder cancer patient

Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients

Clinical significance of serum tumor marker for advanced gastric cancer with palliative chemotherapy: A retrospective study.

Values of serum CA125, NSE and 24‐hour urine VMA in diagnosis and prediction of treatment of paediatric neuroblastoma

Expression and Prognostic Significance of Galectin-1 and Galectin-3 in Benign Nevi and Melanomas

Serum Biomarker Status with a Distinctive Pattern in Prognosis of Gastroenteropancreatic Neuroendocrine Carcinoma.